Skip to content

Use of non invasive brain stimulation to treat depression in adolescents.

Use of Theta burst stimulation in adolescents with depression: Evaluating acceptability, safety, tolerability, and efficacy.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016219
Enrollment
30
Registered
2018-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified

Interventions

Intervention1: Theta Burst Stimulation (TBS): TBS refers to a rTMS (repetitive transcranial magnetic stimulation) protocol where pulses are applied in bursts of three, delivered at a frequency of 50 H

Sponsors

NIMHANS hospital
Lead Sponsor
Dr Satish Girimaji
Collaborator
Dr Urvaksh Mehta
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. 12-18 years of age, either gender 2. Moderate â?? Severe Depression (as per DSM 5) 3. In patients in department of child & adolescent psychiatry,NIMHANS 4. Parents willing to consent for the study

Exclusion criteria

Exclusion criteria: 1. Intracranial implants (cochlear implants, aneurysmal clips) 2. Acute emergencies like high suicidal risk and catatonia where ECT is considered as a first line treatment 3. Current/Past history / family history of epilepsy 4. Adolescents on Methylphenidate , Bupropion , Clozapine, Tricyclic antidepressants 5. Active Neurological illness / head injury 6. Autism spectrum disorder , Intellectual developmental disorder 7. Organic mood disorders 8. Chronic physical illness

Design outcomes

Primary

MeasureTime frame
To measure Adverse effect of TMS using structured tool devised by Pascal Leone , Visual analogue scale , Neuropsychological tests and rate of discontinuationTimepoint: baseline , daily after TMS sessions , 1 week , 2 week , 3 month

Secondary

MeasureTime frame
acceptability of TBS as a treatment modality as measured by ratio of those who accept TMS as treatment modality to those who were offered sameTimepoint: 2 weeks;efficacy in terms of change in severity of depression over period of 12 weeks as measured by fall in CDRS-R scoresTimepoint: Baseline , 2 weeks , 3 months

Countries

India

Contacts

Public ContactSiddhesh Shere

NIMHANS , Bangalore

drgirimaji@gmail.com9480829465

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 15, 2026